Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
GLOBETECH PUBLISHING

New Blood Test Identifies Sudden Cardiac Death Risk

By Labmedica International staff writers
Posted on 09 Jul 2014
Image: The two step amplification process involved in Multiplex Amplification of Specific Targets for Resequencing (MASTR) assay technology (Image courtesy of Multiplicom).
Image: The two step amplification process involved in Multiplex Amplification of Specific Targets for Resequencing (MASTR) assay technology (Image courtesy of Multiplicom).
A blood test has been developed which will determine the genetic risk of Sudden Cardiac Death (SCD) which affects one in a thousand people, and it is especially healthy young individuals who are affected by SCD.

Genetic predisposition plays an important role as family members of affected individuals have a 50% risk of inheriting the same genetic predisposition to develop cardiac disease and therefore early detection of hereditary heart disease in high-risk families can save lives.

Scientists at University of Antwerp (Belgium) working with clinicians at the Antwerp University Hospital (Belgium) have been using a new molecular genetic test to determine the risk of SCD. Patients and family members are seen by a multidisciplinary team of geneticist, cardiologist and psychosocial workers. This collaboration offers the opportunity to answer both genetic and cardiological questions during the same clinic visit. Moreover, both the clinical and genetic work-up of families is streamlined to the benefit of the patient.

The genetic test is called PED MASTR (Multiplicom; Niel, Belgium) and is already in use at the center of medical genetics of the University of Antwerp and the Antwerp University Hospital and will be launched worldwide from September 2014. With the development of the PED MASTR it has become feasible and fast to fully analyze the high number of genes involved for SCD causing mutations.

Multiplicom’s Multiplex Amplification of Specific Targets for Resequencing (MASTR) assays enable multiplex polymerase chain reaction (PCR) amplification of all required coding sequences of the genes of interest in a limited number of PCR reactions. Further downstream pooling of DNA amplicons and barcoding individual samples of the MASTR assays with contemporary massive parallel sequencing (MPS) technologies, allows simple, high throughput and cost-effective sequencing for both research and diagnostic purposes.

Dirk Pollet, PhD, the CEO of Multiplicom, said, “This new kit, using our MASTR technology, comprising 51 genes, allows physicians to identify all genetic mutations at once and use this information to propose appropriate treatment. This has been a unique project, bringing together the expertise of clinicians, geneticists and diagnostic developers to deliver to society a product that will save young lives.” The clinical scientists noted that: “This test nicely complements our existing clinical cardiac- and genetic expertise and offers the option to presymptomatic but mutation-carrying individuals to implement preventive measures to avoid SCD.”

Related Links:

University of Antwerp
Antwerp University Hospital
Multiplicom



DiagCor Bioscience
Sekisui Diagnostics
VIRCELL
comments powered by Disqus
Life Technologies

Channels

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Pathology

view channel
Image: Histopathology of increased endomysial connective tissue from a patient with Duchenne Muscular Dystrophy. Necrotic fibers arrowed (Photo courtesy of Washington University in St. Louis).

New Partnership Designed to Automate Dystrophin Measurement

A developer of innovative ribonucleic acid (RNA)-based therapeutics, Sarepta Therapeutics, Inc. ( Cambridge, MA, USA), and a leading tissue-based companion diagnostics firm, Flagship Biosciences LLC (Boulder,... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.